<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Digitalis (cardiac glycoside) poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Digitalis (cardiac glycoside) poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Digitalis (cardiac glycoside) poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael D Levine, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayrn D O'Connor, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In 1785, Sir William Withering described the use of the foxglove plant, <em>Digitalis purpurea</em>, for treatment of heart failure [<a href="#rid1">1</a>]. More than 200 years later, cardiac glycosides are still prescribed for heart failure with reduced ejection fraction and for rate control in atrial fibrillation or flutter.</p><p>While its clinical use has declined, adverse events related to <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> continues to account for significant morbidity and mortality [<a href="#rid2">2</a>]. In 2017, there were 1689 cases of cardiac glycoside exposures reported to United States poison control centers. Of these, 559 patients suffered moderate or major toxicity and 23 died [<a href="#rid3">3</a>].</p><p>In addition to the pharmaceutical cardiac glycoside, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, other naturally occurring cardiac glycosides have associated toxicity. These include various plants (eg, foxglove, dogbane, red squill, lily of the valley, oleander, henbane) and bufadienolides, cardioactive steroids found in the skin of toads belonging to the Bufonidae family [<a href="#rid4">4</a>]. In 2018, there were an additional 1566 cases of cardiac glycoside exposure reported to United States poison control centers from various plant species [<a href="#rid3">3</a>].</p><p>The pharmacology, diagnosis, and management of acute and chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> poisoning will be reviewed here. The dosing of digoxin-specific antibody (Fab) fragments for the treatment of digoxin toxicity and the therapeutic use of digoxin are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/328.html" rel="external">"Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1051.html" rel="external">"Treatment with digoxin: Initial dosing, monitoring, and dose modification"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span><span class="headingEndMark"> — </span>Cardiac glycosides all possess a steroid nucleus with an unsaturated lactone at the C17 position, and at least one glycosidic residue at the C3 position  (<a class="graphic graphic_figure graphicRef65821" href="/z/d/graphic/65821.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]. Cardiac glycosides are used primarily to increase inotropy in cardiac myocytes but also affect cells in the autonomic nervous system and vascular smooth muscle [<a href="#rid5">5-7</a>].</p><p>Normal depolarization of the cardiac myocyte begins with the opening of the fast sodium channels. The resulting increase in intracellular sodium, and subsequent change in the resting membrane potential, opens voltage-gated calcium channels. The initial influx of calcium induces further release of calcium from the sarcoplasmic reticulum, which results in muscle contraction [<a href="#rid8">8</a>]. Sodium is then removed from the cell by, among several mechanisms, the sodium-potassium-ATPase. Some calcium is removed from the cell by the sodium-calcium antiporter.</p><p>Cardiac glycosides reversibly inhibit the sodium-potassium-ATPase, causing an increase in intracellular sodium and a decrease in intracellular potassium [<a href="#rid1">1,5</a>]. The increase in intracellular sodium prevents the sodium-calcium antiporter from expelling calcium from the myocyte, which increases intracellular calcium. The net increase in intracellular calcium augments inotropy [<a href="#rid5">5,9</a>]. Cardiac glycosides also increase vagal tone, which results in decreased conduction through the sinoatrial and atrioventricular nodes [<a href="#rid5">5</a>].</p><p>Excessive intracellular calcium may cause delayed after-depolarizations, which may in turn lead to premature contractions and trigger dysrhythmias. Cardiac glycosides shorten repolarization of the atria and ventricles, decreasing the refractory period of the myocardium, thereby increasing automaticity and the risk for dysrhythmias [<a href="#rid10">10,11</a>].</p><p>The effects of cardiac glycosides on peripheral vasculature can vary [<a href="#rid11">11-13</a>]. In patients without heart failure, cardiac glycosides can increase vasoconstriction. However, in patients with advanced decompensated heart failure, digitalis has been shown to reduce plasma renin concentrations, causing peripheral vasodilation [<a href="#rid11">11</a>]. This difference is likely due to enhanced responsiveness of the baroreceptors in patients with chronic heart failure [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">KINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> is the only cardiac glycoside commonly used for medicinal purposes. Important pharmacokinetic properties of digoxin are summarized in the attached table  (<a class="graphic graphic_table graphicRef60113" href="/z/d/graphic/60113.html" rel="external">table 1</a>).</p><p><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> has a narrow therapeutic index and toxicity is common [<a href="#rid14">14</a>]. Furthermore, dosing adjustments must be made whenever significant alterations occur in factors affecting absorption, distribution, or elimination. Such factors are numerous and include changes in volume of distribution due to age or increased adipose stores, diminished protein binding from conditions causing hypoalbuminemia, and kidney impairment resulting in decreased elimination.</p><p><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> is a substrate of intestinal and renal p-glycoprotein. P-glycoprotein is an efflux pump that excretes many drugs into the intestine or proximal renal tubule, thereby lowering serum concentrations. Drugs that alter p-glycoprotein activity can increase serum digoxin concentrations [<a href="#rid15">15,16</a>]. Examples of such drugs include <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>  (<a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 2</a>) [<a href="#rid17">17,18</a>].</p><p>The molecular weight of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is large, making extracorporeal elimination ineffective. (See <a class="local">'Extracorporeal removal'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Cardiac glycosides, both naturally occurring and from pharmaceutical sources, can cause toxicity.</p><p>Critical clinical manifestations of toxicity are usually cardiac but may include gastrointestinal and neurologic signs. The diagnosis of cardiac glycoside toxicity is based upon clinical and electrocardiographic manifestations rather than isolated elevated serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentrations. Furthermore, presentation can vary depending upon whether toxicity is acute or chronic.</p><p class="headingAnchor" id="H5"><span class="h2">History</span><span class="headingEndMark"> — </span>Determine the agent, amount taken, time of ingestion, and any coingestants when possible. The time of ingestion or last dose is especially important for interpreting serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration. A serum concentration drawn fewer than six hours since ingestion, may be falsely elevated due to incomplete drug distribution. It is also important to determine if toxicity is acute or chronic by identifying if the patient normally takes digoxin therapeutically or if the patient ingested someone else's prescription. (See <a class="local">'Serum digoxin concentration: Performance and interpretation'</a> below.)</p><p>Inquire about gastrointestinal, cardiac, and neurologic manifestations, which are typical findings associated with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity. Gastrointestinal signs and symptoms are prominent with acute digoxin toxicity. It is important to ask about neurocognitive signs and symptoms, which are common and can be more subtle with chronic toxicity. (See <a class="local">'Clinical manifestations'</a> below.)</p><p>Inquire about symptoms that suggest a preceding acute illness, such as a gastroenteritis, which may lead to dehydration or acute kidney insufficiency and contribute to the development of chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity [<a href="#rid19">19</a>].</p><p>Inquire also about symptoms that suggest hypoperfusion, such as confusion or abdominal pain, which may stem from mesenteric ischemia [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2559.html" rel="external">"Overview of intestinal ischemia in adults", section on 'Clinical features'</a>.)</p><p>Obtain a thorough medication history to determine if any recent additions or dosing changes were made. Several medications, including <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, can increase serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentrations  (<a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 2</a>). Ask if any medications were recently discontinued, as the discontinuation of a drug that decreases digoxin concentrations can cause digoxin to accumulate.</p><p class="headingAnchor" id="H6"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>After initial evaluation of the patient's airway and breathing, the clinician should assess the patient's vital signs. Bradycardia is frequently encountered in cardiac glycoside toxicity.</p><p>Look for evidence of hypoperfusion and end organ dysfunction. Pay particular attention to mentation and neurologic status, keeping in mind that such effects are often due to direct toxicity but may be secondary to cerebral hypoperfusion. Look for symptoms and signs suggestive of acute mesenteric ischemia, which is a rare complication. (See  <a class="medical medical_review" href="/z/d/html/2559.html" rel="external">"Overview of intestinal ischemia in adults", section on 'Physical examination'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>In both acute and chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity, cardiac effects are of the greatest concern. The cardiac manifestations of cardiac glycoside toxicity can include virtually any type of dysrhythmia with the exception of rapidly conducted atrial dysrhythmias [<a href="#rid10">10</a>]. Cardiac-glycoside-related dysrhythmias are discussed below and separately. (See <a class="local">'Electrocardiogram'</a> below and  <a class="medical medical_review" href="/z/d/html/944.html" rel="external">"Cardiac arrhythmias due to digoxin toxicity"</a>.)</p><p>Other symptoms of acute and chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity may overlap, but a few important differences should be noted. With an acute ingestion, the patient may remain asymptomatic for several hours then develop significant gastrointestinal symptoms, such as anorexia, nausea, vomiting, and abdominal pain. Neurologic manifestations such as confusion and weakness, independent of hemodynamic parameters, are common and often develop later upon distribution of the drug into the central nervous system. Electrolyte abnormalities occur with both acute and chronic toxicity and are discussed further below. (See <a class="local">'Electrolyte abnormalities'</a> below.)</p><p>Chronic toxicity is often more difficult to diagnose, as symptom onset tends to be more insidious and may occur over a period ranging from days to months. Gastrointestinal symptoms, such as anorexia, nausea, and vomiting, can occur but may be less pronounced. Neurologic manifestations, such as lethargy, fatigue, delirium, confusion, disorientation, and weakness, may be prominent in chronic toxicity [<a href="#rid21">21</a>]. Often patients are brought to medical attention by family members who note a change in mental status or cognition.</p><p>Visual changes associated with cardiac glycoside toxicity are varied and may include alterations in color vision (chromatopsia), diplopia, photophobia, decreased visual acuity, photopsia, scotomas, or blindness. Chromatopsia, specifically xanthopsia (objects appear yellow), is classically associated with cardiac glycoside toxicity but is frequently absent and not necessary for diagnosis.</p><p class="headingAnchor" id="H9"><span class="h1">LABORATORY AND ECG EVALUATION</span></p><p class="headingAnchor" id="H10"><span class="h2">Approach to testing</span><span class="headingEndMark"> — </span>In the patient with suspected <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity, the following studies should be obtained:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration:</p><p></p><p class="bulletIndent1">For an acute overdose, obtain a serum concentration measurement on presentation and approximately six hours after the ingestion; for chronic toxicity, obtain a concentration on presentation and interpret it in the context of last administered dose (&gt;6 hours for post-distribution concentration)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum potassium concentration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Creatinine and blood urea nitrogen (BUN) to assess kidney function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serial electrocardiograms (ECGs)</p><p></p><p>In the setting of an intentional ingestion, the following studies should also be obtained:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> and salicylate concentrations, to rule out these common coingestants</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in women of childbearing age</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Electrolyte abnormalities</span><span class="headingEndMark"> — </span>Inhibition of the sodium-potassium-ATPase, in both heart and skeletal muscle, leads to an increase in extracellular potassium. Thus, hyperkalemia is an important marker of acute cardiac glycoside toxicity, and a predictor of mortality. Other electrolyte abnormalities may also occur in the setting of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> poisoning. (See <a class="local">'Pharmacology and cellular toxicology'</a> above.)</p><p>In acute toxicity, the degree of hyperkalemia correlates with mortality. This was first shown in a classic study performed before the advent of antidotal therapy using digoxin-specific antibody (Fab) fragments. In this study of 91 patients primarily with acute <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> poisoning from intentional overdose, researchers noted that no patient with an initial potassium concentration above 5.5 mEq/L (or mmol/L) survived, while no patient with a potassium concentration below 5 mEq/L died [<a href="#rid22">22</a>]. This correlation has also been demonstrated in plant cardiac glycoside ingestions [<a href="#rid23">23,24</a>].</p><p>In the setting of chronic toxicity, hypokalemia may be a significant concern. Several electrolyte abnormalities, including hypokalemia, hypomagnesemia, and hypercalcemia, increase patient susceptibility to the toxic effects of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> [<a href="#rid14">14</a>]. Loop diuretics to treat heart failure are the most common cause of hypokalemia in these patients, but other causes of hypokalemia (eg, diarrhea or vomiting) do occur.</p><p>Kidney dysfunction is commonly encountered in the setting of chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity and is often what precipitates the rise in the digoxin concentration. Therefore, assessment of kidney function is essential and should include measurements of BUN and creatinine, as well as urine output to assess kidney perfusion. The adjustments needed for digoxin dosing in the setting of kidney insufficiency are described separately. (See  <a class="medical medical_review" href="/z/d/html/1051.html" rel="external">"Treatment with digoxin: Initial dosing, monitoring, and dose modification", section on 'Dose adjustments'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Serum digoxin concentration: Performance and interpretation</span><span class="headingEndMark"> — </span>The therapeutic window of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is narrow, with substantial overlap between “therapeutic” and “toxic” serum concentrations, which can be affected by many factors (eg, impaired kidney function, other medications). Therefore, determining an appropriate therapeutic serum digoxin concentration can be difficult. Issues related to the therapeutic serum concentration of digoxin are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1051.html" rel="external">"Treatment with digoxin: Initial dosing, monitoring, and dose modification", section on 'Monitoring serum digoxin'</a>.)</p><p>A quantitative serum total <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration is readily measured in most hospital laboratories. The approximate therapeutic range for patients in heart failure is 0.5 to 0.8 ng/mL (0.65 to 1 nmol/L), with a typical immunoassay reference range being 0.8 to 2.0 ng/mL (1 to 2.6 nmol/L). Ideally, blood samples should be collected four hours after an intravenous dose or six hours after an oral dose in order to account for drug distribution and obtain an accurate measurement. If the sample is obtained soon after administration or ingestion, the serum digoxin concentration may reflect a pre-distribution phase and be falsely elevated (ie, not correlating with a tissue concentration).</p><p>The serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration does <strong>not</strong> necessarily correlate with toxicity. Numerous reports have described asymptomatic patients with a "toxic" concentration, while others described patients with significant toxicity despite a serum digoxin concentration in the therapeutic range [<a href="#rid21">21,25-27</a>]. Nevertheless, an observational study of 171 digoxin poisonings reported a correlation between a higher mean serum digoxin concentration and 30-day mortality [<a href="#rid28">28</a>].</p><p>In the setting of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity, serum digoxin concentrations can be used to determine the dosing of antidotal therapy with Fab fragments. (See <a class="local">'Antidotal therapy with antibody (Fab) fragments'</a> below.)</p><p>The <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> immunoassay is specifically designed to measure digoxin; however, cross reactivity with other cardiac glycosides does occur. In cases of toxicity from other cardiac glycosides, such as those found in various plant species, digoxin concentration should <strong>not </strong>be used to calculate antidotal therapy with Fab fragments due to incomplete cross-reactivity and absence of a correlation between the quantitative result and degree of toxicity.</p><p>Following the administration of Fab fragments, serum immunoassays of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> are unreliable, as they measure both bound and unbound drug. Fab treatment frequently causes an elevation in the serum digoxin concentration despite a free digoxin concentration approaching zero [<a href="#rid29">29,30</a>]. Consequently, total digoxin concentrations should not be obtained or used clinically following Fab fragment administration. Measurement of "free" digoxin concentrations may be utilized and followed after treatment with Fab fragments, although free digoxin concentrations may not be routinely available in some centers.</p><p>Elevated <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentrations have been identified in pregnant women, newborns, and patients with acromegaly, subarachnoid hemorrhage, liver disease, and kidney failure due to endogenous digoxin-like substances [<a href="#rid31">31</a>]. The clinical significance of endogenous digoxin-like substances remains unknown.</p><p class="headingAnchor" id="H13"><span class="h2">Electrocardiogram</span><span class="headingEndMark"> — </span>Cardiac glycoside toxicity can produce a range of cardiac dysrhythmias, and rhythm disturbances may evolve and change rapidly. Thus, performing continuous cardiac monitoring and obtaining serial electrocardiograms (ECG) is important in the setting of toxicity. An ECG should be obtained upon presentation and repeated with any change in the patient's clinical condition or any significant alteration in the rhythm or waveform on the cardiac monitor.</p><p>Premature ventricular contractions are the most common rhythm disturbance caused by <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity [<a href="#rid32">32</a>]. Others include bradycardia, atrial tachydysrhythmias with AV block, ventricular bigeminy, junctional rhythms, various degrees of AV nodal blockade, ventricular tachycardia, and ventricular fibrillation. Bidirectional ventricular tachycardia, while not pathognomonic for digoxin toxicity, is encountered in rare instances; digoxin is one of only a few xenobiotics known to produce this dysrhythmia  (<a class="graphic graphic_waveform graphicRef71796" href="/z/d/graphic/71796.html" rel="external">waveform 1</a>).</p><p>Ventricular dysrhythmias are reportedly more common in chronic toxicity and in patients with chronic heart disease [<a href="#rid25">25</a>]. A detailed description of the dysrhythmias caused by cardiac glycosides is found separately. (See  <a class="medical medical_review" href="/z/d/html/944.html" rel="external">"Cardiac arrhythmias due to digoxin toxicity"</a>.)</p><p>The so-called "digitalis effect" on the ECG consists of T wave changes (flattening or inversion), QT interval shortening, scooped ST segments with ST depression in the lateral leads, and increased amplitude of the U waves. It is often seen with chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> use and does not correlate well with clinical manifestations of toxicity  (<a class="graphic graphic_waveform graphicRef56737" href="/z/d/graphic/56737.html" rel="external">waveform 2</a>) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H323455140"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of cardiac glycoside toxicity is made clinically based upon a combination of a history of exposure, suggestive clinical features, and/or electrocardiographic manifestations. Isolated elevated serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentrations may confirm exposure but do not correlate consistently with clinical manifestations of toxicity. Following an acute overdose, the patient may remain asymptomatic for several hours and then manifest a number of symptoms and signs, including cardiac (dysrhythmia), gastrointestinal (anorexia, nausea, vomiting, and abdominal pain), and neurologic findings (confusion, weakness, delirium). The cardiac manifestations of cardiac glycoside toxicity can include virtually any type of dysrhythmia, with the exception of rapidly conducted atrial dysrhythmias. Hyperkalemia is an important marker of and prognostic indicator for acute toxicity. Chronic toxicity is often more difficult to diagnose, as symptom onset tends to be more insidious and digoxin concentrations may be minimally elevated.</p><p class="headingAnchor" id="H33651379"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Poisoning with beta blockers, calcium channel blockers, and alpha agonists (eg, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>) can present in a similar fashion to <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity, with bradycardia and hypotension being prominent features. An elevated serum digoxin concentration distinguishes digoxin poisoning. In addition, significant toxicity from calcium channel blockers generally produces hyperglycemia. Clonidine poisoning leads to greater CNS depression, respiratory depression, and miosis than is seen with digoxin poisoning.</p><p>Nontoxicologic etiologies may also present with symptoms and signs similar to cardiac glycoside poisoning. These may include sick-sinus syndrome, hypothermia, hypothyroidism, myocardial infarction, and hyperkalemia from other causes.</p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H15"><span class="h2">Basic measures and dysrhythmias</span><span class="headingEndMark"> — </span>When cardiac glycoside toxicity is suspected, the following measures should be performed:</p><p class="bulletIndent1"><span class="glyph">●</span>Assess airway, breathing, and circulation; stabilize as necessary</p><p class="bulletIndent1"><span class="glyph">●</span>Place the patient on continuous cardiac and pulse oximetry monitors</p><p class="bulletIndent1"><span class="glyph">●</span>Establish intravenous (IV) access</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain an electrocardiogram (ECG)</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain a fingerstick glucose measurement if there is any alteration in mental status (see <a class="local">'Approach to testing'</a> above)</p><p></p><p>The treatment for any clinically significant dysrhythmia associated with hemodynamic instability from cardiac glycoside toxicity is digoxin-specific antibody (Fab) fragments. Treatment decisions must be made on an individual basis and are often made in conjunction with a medical toxicologist or a poison control center. (See <a class="local">'Additional resources'</a> below.)</p><p>Symptomatic bradycardia or bradydysrhythmia can be treated with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> (0.5 mg IV in adults; 0.02 mg/kg IV in children, minimum dose 0.1 mg) and hypotension with IV boluses of isotonic crystalloid as temporizing measures, particularly if Fab fragments are not immediately available. In patients with history of decompensated heart failure, judicious use of fluids may be required. Life-threatening ventricular dysrhythmias are treated according to the algorithms of advanced cardiac life support. (See  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Antidotal therapy with antibody (Fab) fragments</span></p><p class="headingAnchor" id="H17"><span class="h3">Indications and general approach</span><span class="headingEndMark"> — </span>Early recognition of cardiac glycoside toxicity and prompt administration of Fab fragments is essential for the successful treatment of severe poisoning [<a href="#rid12">12,33</a>]. Fab fragments are highly effective and safe and have transformed the management of cardiac glycoside poisoning [<a href="#rid33">33,34</a>]. One vial binds approximately 0.5 mg of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>. </p><p>The dosing of Fab fragments is based upon the clinical setting (eg, agent and amount ingested; serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration) and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/328.html" rel="external">"Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity"</a>.)</p><p>Fab fragments should be given in all cases of severe cardiac glycoside poisoning, as there is no alternative therapy with comparable efficacy and safety. We suggest Fab fragments be given to patients with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity and any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening or hemodynamically unstable dysrhythmia (eg, ventricular tachycardia; ventricular fibrillation; asystole; complete heart block; Mobitz II heart block; symptomatic bradycardia) [<a href="#rid35">35</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperkalemia (serum potassium &gt;5 to 5.5 meq/L [&gt;5 to 5.5 mmol/L])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of end-organ dysfunction from hypoperfusion (eg, kidney failure, altered mental status)</p><p></p><p>We generally do not advocate treatment with Fab fragments based solely upon the serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration or the amount ingested; treatment is predicated on the clinical manifestations described above. However, some advocate giving Fab fragments if the serum digoxin concentration is greater than 10 ng/mL (13 nmol/L) at steady state in acute ingestions, or greater than 4 ng/mL (5.1 nmol/L) in chronic ingestions, or when an adult ingests more than 10 mg or a child more than 4 mg acutely.</p><p>Cross reactivity exists between <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> and other cardiac glycosides. Therefore, digoxin-specific antibodies can be used to treat poisoning involving cardiac glycosides from both plants and animals [<a href="#rid23">23,36,37</a>]. However, the dosing of Fab fragments should be done empirically in such cases because the degree of toxicity in naturally occurring cardiac glycosides does not correlate with the serum digoxin concentration. (See <a class="local">'Serum digoxin concentration: Performance and interpretation'</a> above.)</p><p>Evidence for the benefit of digoxin-specific Fab fragments is found in the many case series that have appeared since their advent in 1976 [<a href="#rid25">25,34,38,39</a>]. Prior to the development of this treatment, the management of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> overdose was difficult and often resulted in life-threatening dysrhythmias.</p><p class="headingAnchor" id="H18"><span class="h3">Patients with pacemakers</span><span class="headingEndMark"> — </span>It may be impossible to determine the underlying cardiac rhythm and thereby detect signs of cardiac glycoside toxicity in patients with paced rhythms. The ECG in such patients may demonstrate a paced rhythm without ventricular ectopy or bradydysrhythmia despite the presence of moderate to severe <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity. We suggest treating these patients with digoxin-specific antibody fragments if hemodynamic instability is present, the serum potassium concentration is above 5 to 5.5 meq/L [&gt;5 to 5.5 mmol/L], or clinical symptoms are significant (eg, encephalopathy) or progressing. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H19"><span class="h2">GI decontamination</span><span class="headingEndMark"> — </span>The administration of activated charcoal (AC) for gastrointestinal decontamination should be viewed as adjunctive and <strong>not</strong> primary therapy in patients with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> poisoning. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p>Patients suspected of having an acute cardiac glycoside intoxication who present to the emergency department within one to two hours of ingestion may benefit from the administration of AC. The standard dose is 1 g/kg (maximum 50 g). The decision to administer AC should be made after ensuring that the patient is alert and adequately protecting their airway. We do <strong>not</strong> advocate insertion of a nasogastric tube in a nonintubated patient solely for the purpose of administering AC. AC is unlikely to benefit patients with chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity.</p><p>Cardiac glycosides undergo some degree of enterohepatic or enteroenteric recirculation and are adsorbed to activated charcoal. However, there are mixed clinical data regarding the efficacy of AC or multi-dose AC (MDAC) in the setting of yellow oleander poisoning: One randomized trial found a reduction in mortality with AC administration [<a href="#rid40">40</a>], while another did not [<a href="#rid41">41</a>].</p><p>When Fab fragments are not available, AC or MDAC are reasonable interventions in patients with yellow oleander poisoning, although efficacy remains unclear. The extrapolation of data from studies of yellow oleander poisoning to poisonings with other glycosides (eg, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>) should be made with caution. Most importantly, neither AC nor MDAC should ever be considered an alternative to Fab fragment therapy for any cardiac glycoside poisoning when Fab fragments are available. Fab fragment therapy remains the essential treatment for cardiac glycoside poisoning. (See <a class="local">'Antidotal therapy with antibody (Fab) fragments'</a> above.)</p><p><a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">Cholestyramine</a> may interrupt enterohepatic recirculation and its use has been reported in patients with acute <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> intoxication and kidney failure for whom Fab fragments were not available [<a href="#rid42">42,43</a>]. Given the limited evidence, its use cannot be recommended.</p><p class="headingAnchor" id="H20"><span class="h2">Electrolyte abnormalities</span></p><p class="headingAnchor" id="H2380890594"><span class="h3">Hyperkalemia</span><span class="headingEndMark"> — </span>Hyperkalemia should be managed depending on whether it is from the <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity itself (which typically occurs in acute toxicity) or if it is due to an underlying or preceding condition (which is more likely to occur in chronic toxicity). (See <a class="local">'Clinical features and diagnosis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute toxicity</strong> – Hyperkalemia resulting from acute <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity is a marker of severity and correlates with the risk of death. Hyperkalemia reflects the degree of inhibition of the sodium-potassium-ATPase pump. Following treatment with digoxin-specific Fab fragments, hyperkalemia due to acute toxicity rapidly corrects as the sodium-potassium ATPase pump function returns and potassium shifts intracellularly. Thus, aggressive treatment with potassium-lowering agents (insulin and dextrose, <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, or ion exchange resins) could cause significant <strong>hypo</strong>kalemia following antidotal therapy [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic toxicity</strong> – Unlike acute <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity, the degree of hyperkalemia and its correlation with the risk of mortality is not as well characterized in chronic digoxin toxicity. A small, retrospective poison center study found that bradycardia and hyperkalemia were associated with fatality in patients with chronic toxicity [<a href="#rid44">44</a>].</p><p></p><p>Hyperkalemia resulting from end-organ damage (eg, acute kidney failure) and independent of either acute or chronic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity may warrant judicious treatment with potassium-binding resins, <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, or insulin/glucose, especially if the patient has electrocardiogram changes consistent with hyperkalemia or if hyperkalemia persists following the administration of Fab fragments. (See  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults", section on 'Patients with a hyperkalemic emergency'</a>.)</p><p class="headingAnchor" id="H4081768450"><span class="h4">Should calcium be administered for hyperkalemia?</span><span class="headingEndMark"> — </span>Because hyperkalemia is not the cause of death and because excessive intracellular calcium is present in <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> poisoning, we do <strong>not</strong> recommend routine administration of calcium in patients with hyperkalemia as a result of digoxin toxicity. In this setting, hyperkalemia is best treated with digoxin-specific antibody fragments. (See <a class="local">'Antidotal therapy with antibody (Fab) fragments'</a> above.)</p><p>Some suggest that calcium should not be given to patients with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity for the treatment of hyperkalemia, but high-quality evidence is lacking. This teaching is based primarily upon five published cases dating back to 1933. Of these five cases, only three patients had a temporal association between calcium administration and digoxin toxicity [<a href="#rid45">45-47</a>]. Some studies have shown that hypercalcemic animals given digoxin developed adverse effects with lower doses than normocalcemic animals [<a href="#rid48">48,49</a>]. However, the serum calcium concentrations in these studies exceeded 20 mg/dL (5 mmol/L) before increased toxicity occurred. Other animal experiments involving lower, more physiologic, serum calcium concentrations did not show increased toxicity [<a href="#rid50">50</a>].</p><p>There are several case reports of patients receiving calcium for treatment of digoxin-induced hyperkalemia without adverse effects [<a href="#rid51">51,52</a>]. In addition, a large retrospective series of patients with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity found no ill effects attributable to the administration of calcium [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H483512932"><span class="h3">Hypokalemia</span><span class="headingEndMark"> — </span>If a patient with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> poisoning is hypokalemic (which is more likely to occur in chronic toxicity), potassium should be repleted since hypokalemia exacerbates toxicity [<a href="#rid21">21</a>]. Many patients with hypokalemia may have coexistent hypomagnesemia, which should be corrected as well. Following treatment with Fab fragments, further reduction in serum potassium is likely and may warrant judicious potassium repletion. (See  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Kidney failure</span></p><p class="headingAnchor" id="H22"><span class="h3">General care</span><span class="headingEndMark"> — </span>Volume depletion from diuretics or gastrointestinal losses can cause prerenal disease, contributing to <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity. Appropriate fluid resuscitation is necessary in such cases. (See  <a class="medical medical_review" href="/z/d/html/2298.html" rel="external">"Etiology, clinical manifestations, and diagnosis of volume depletion in adults"</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Fab fragment dosing</span><span class="headingEndMark"> — </span>The dose of digoxin-specific antibody (Fab) fragments does not need to be adjusted in patients with kidney failure, but the elimination of both <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> and Fab fragments is markedly prolonged in this setting [<a href="#rid54">54-56</a>]. Cases of recurrent digoxin toxicity, including ventricular dysrhythmias, have been reported 72 to 90 hours after antidotal therapy [<a href="#rid29">29</a>]. Thus, any patient with significant kidney dysfunction who receives Fab fragments should be observed in a closely monitored setting for a minimum of 72 hours.</p><p class="headingAnchor" id="H24"><span class="h3">Extracorporeal removal</span><span class="headingEndMark"> — </span>Because of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>'s large volume of distribution and molecular weight, extracorporeal removal is not beneficial. Neither hemoperfusion nor hemodialysis has been shown to be helpful in the management of digoxin toxicity [<a href="#rid57">57-59</a>].</p><p>The combination of Fab fragments and plasmapheresis has been used with apparent success in a few patients with kidney failure [<a href="#rid60">60,61</a>]. Nevertheless, we do not routinely recommend this approach. Instead, we administer Fab fragments for the usual indications and observe the patient with kidney failure in a closely monitored setting over several days. Additional Fab fragments are given if signs of toxicity recur.</p><p class="headingAnchor" id="H25"><span class="h2">Disposition</span><span class="headingEndMark"> — </span>All patients with signs of cardiac glycoside toxicity should be admitted to the hospital with continuous cardiac monitoring. Patients who have unstable cardiac rhythms and those with underlying cardiac disease or major comorbidities are admitted to an intensive care setting.</p><p>Patients with less severe signs of cardiac glycoside toxicity who do not receive antidotal therapy with Fab fragments are admitted for monitoring, which should include serial measurements of their serum potassium and <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentrations. Serial electrocardiograms (ECG) should be obtained. Although the time interval for obtaining ECGs will vary depending on the patient's clinical condition, a new ECG should be obtained if any significant changes are noted on the cardiac monitor.</p><p>Patients with suspected cardiac glycoside toxicity but without significant manifestations or kidney disease are placed on cardiac monitoring and observed for approximately six hours. If they remain asymptomatic and a repeat serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration is not increasing, they may be discharged.</p><p class="headingAnchor" id="H26"><span class="h1">PEDIATRIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>While less common, pediatric ingestions of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> are potentially life threatening [<a href="#rid62">62</a>]. Toxicity among children generally presents with signs and symptoms similar to adults, but with a few important exceptions. Children are more likely to present with bradydysrhythmias and heart block, rather than ventricular dysrhythmias [<a href="#rid63">63</a>]. In addition, children may be more resistant to digoxin's cardiotoxic effects than adults at an equivalent serum concentration [<a href="#rid25">25</a>].</p><p>The treatment of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity, including the indications for antidotal therapy with digoxin-specific antibody (Fab) fragments, remains unchanged. The dosing of Fab fragments is based upon the clinical setting (eg, agent and amount ingested; serum digoxin concentration) and is discussed in detail separately. The indications for treatment are described above. (See  <a class="medical medical_review" href="/z/d/html/328.html" rel="external">"Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity"</a> and <a class="local">'Antidotal therapy with antibody (Fab) fragments'</a> above.)</p><p>In addition to ingesting <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, children may ingest cardiac glycoside-containing plants with resultant toxic effects. The diagnosis and management of such ingestions is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6507.html" rel="external">"Potentially toxic plant ingestions in children: Clinical manifestations and evaluation", section on 'Cardiac glycosides (eg, oleander, foxglove)'</a> and  <a class="medical medical_review" href="/z/d/html/16521.html" rel="external">"Toxic plant ingestions in children: Management"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H1031535494"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H2803096176"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> (cardiac glycoside) toxicity include cardiac, gastrointestinal, and neurologic signs. Chronic toxicity is more difficult to diagnose, as symptom onset tends to be more insidious. (See <a class="local">'Clinical features and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dysrhythmia is the most dangerous manifestation of cardiac glycoside poisoning and can include virtually any type of dysrhythmia with the exception of rapidly conducted atrial dysrhythmias.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal effects include anorexia, nausea, vomiting, and abdominal pain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic signs such as confusion and weakness may be present. Visual changes may occur, including alterations in color vision, the development of scotomas, or blindness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for cardiac glycoside intoxication includes poisoning with beta blockers, calcium channel blockers, or alpha agonists (eg, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>), as well as nontoxicologic etiologies such as sick-sinus syndrome, hypothermia, hypothyroidism, myocardial infarction, and hyperkalemia unrelated to <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory and electrocardiogram (ECG) evaluation</strong> – In the patient with suspected <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> toxicity, a serum digoxin concentration, serum potassium concentration, creatinine and blood urea nitrogen (BUN), and serial ECGs should be obtained. (See <a class="local">'Laboratory and ECG evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of cardiac glycoside toxicity is made clinically based upon a combination of a history of exposure, suggestive clinical features, and/or ECG manifestations. Isolated elevated serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentrations may confirm exposure but do not correlate consistently with clinical manifestations of toxicity. The therapeutic range of serum digoxin is 0.8 to 2 ng/mL (1 to 2.6 nmol/L). (See <a class="local">'Diagnosis'</a> above and <a class="local">'Serum digoxin concentration: Performance and interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of management</strong> – Management includes standard supportive care; assessing and stabilizing airway, breathing, and circulation; gastrointestinal decontamination; and antidotal therapy with digoxin-specific antibody (Fab) fragments. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As temporizing measures, bradycardia can be treated with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> (0.5 mg intravenously [IV] in adults, 0.02 mg/kg IV in children, minimum dose 0.1 mg).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypotension is likely due to underlying dysrhythmia, which should be addressed. If hypovolemia is suspected, administer IV boluses of isotonic crystalloid. (See <a class="local">'Basic measures and dysrhythmias'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with history of decompensated heart failure or kidney failure, judicious use of fluids may be required. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a patient with <strong>acute</strong> cardiac glycoside intoxication, hyperkalemia reflects the degree of toxicity and risk of death. Aggressive treatment of hyperkalemia does <strong>not</strong> reduce mortality and may increase the risk of hypokalemia following treatment with Fab fragments. Thus, aggressive management of hyperkalemia is typically not warranted. (See <a class="local">'Electrolyte abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal decontamination</strong> – Patients suspected of having acute cardiac glycoside intoxication who present to the emergency department within one to two hours of ingestion may benefit from the administration of activated charcoal. The standard dose is 1 g/kg (maximum 50 g). The decision to administer activated charcoal should be made after ensuring that the patient is alert and adequately protecting their airway. (See <a class="local">'GI decontamination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Digoxin-specific Fab fragments</strong> – In a patient with clinically significant manifestations of cardiac glycoside poisoning, we recommend treatment with digoxin-specific Fab fragments (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Significant findings include (see <a class="local">'Antidotal therapy with antibody (Fab) fragments'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Life-threatening dysrhythmia (eg, ventricular tachycardia; ventricular fibrillation; asystole; complete heart block; Mobitz II heart block; symptomatic bradycardia)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of end-organ dysfunction (eg, kidney failure, altered mental status)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperkalemia (serum potassium &gt;5 to 5.5 meq/L [&gt;5 to 5.5 mmol/L])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Digoxin</strong><strong> concentration monitoring after digoxin-specific Fab administration</strong> –<strong> </strong>In a patient who received antidotal therapy with Fab fragments, total <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentrations should not be obtained as they measure both bound (inactive) and unbound drug. Monitoring of clinical response is typically sufficient, but if concentration monitoring is needed, only free serum digoxin concentrations can be interpreted. (See <a class="local">'Serum digoxin concentration: Performance and interpretation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis 2002; 44:251.</a></li><li><a class="nounderline abstract_t">Angraal S, Nuti SV, Masoudi FA, et al. Digoxin Use and Associated Adverse Events Among Older Adults. Am J Med 2019; 132:1191.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li><a class="nounderline abstract_t">Brubacher JR, Lachmanen D, Ravikumar PR, Hoffman RS. Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. Toxicon 1999; 37:931.</a></li><li><a class="nounderline abstract_t">Botelho AFM, Pierezan F, Soto-Blanco B, Melo MM. A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential. Toxicon 2019; 158:63.</a></li><li><a class="nounderline abstract_t">Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.</a></li><li><a class="nounderline abstract_t">Newton GE, Tong JH, Schofield AM, et al. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 1996; 28:155.</a></li><li class="breakAll">Matthews CG. Cellular Physiology of Nerve and Muscle, 3rd, Blackwell Science, Malden 1998.</li><li><a class="nounderline abstract_t">Demiryürek AT, Demiryürek S. Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton Autacoid Pharmacol 2005; 25:35.</a></li><li><a class="nounderline abstract_t">Ma G, Brady WJ, Pollack M, Chan TC. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med 2001; 20:145.</a></li><li><a class="nounderline abstract_t">Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol 1985; 56:896.</a></li><li><a class="nounderline abstract_t">Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265.</a></li><li><a class="nounderline abstract_t">Tisdale JE, Gheorghiade M. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure. Am J Cardiol 1992; 69:34G.</a></li><li><a class="nounderline abstract_t">Lip GY, Metcalfe MJ, Dunn FG. Diagnosis and treatment of digoxin toxicity. Postgrad Med J 1993; 69:337.</a></li><li><a class="nounderline abstract_t">Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147.</a></li><li><a class="nounderline abstract_t">Drescher S, Glaeser H, Mürdter T, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003; 73:223.</a></li><li><a class="nounderline abstract_t">Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003; 35:417.</a></li><li><a class="nounderline abstract_t">Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001; 12:505.</a></li><li><a class="nounderline abstract_t">Cauffield JS, Gums JG, Grauer K. The serum digoxin concentration: ten questions to ask. Am Fam Physician 1997; 56:495.</a></li><li><a class="nounderline abstract_t">Guglielminotti J, Tremey B, Maury E, et al. Fatal non-occlusive mesenteric infarction following digoxin intoxication. Intensive Care Med 2000; 26:829.</a></li><li><a class="nounderline abstract_t">Bhatia SJ. Digitalis toxicity--turning over a new leaf? West J Med 1986; 145:74.</a></li><li><a class="nounderline abstract_t">Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol 1973; 6:153.</a></li><li><a class="nounderline abstract_t">Eddleston M, Rajapakse S, Rajakanthan, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet 2000; 355:967.</a></li><li><a class="nounderline abstract_t">Eddleston M, Ariaratnam CA, Sjöström L, et al. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital. Heart 2000; 83:301.</a></li><li><a class="nounderline abstract_t">Bayer MJ. Recognition and management of digitalis intoxication: implications for emergency medicine. Am J Emerg Med 1991; 9:29.</a></li><li><a class="nounderline abstract_t">Smith TW. New advances in the assessment and treatment of digitalis toxicity. J Clin Pharmacol 1985; 25:522.</a></li><li><a class="nounderline abstract_t">Sonnenblick M, Abraham AS, Meshulam Z, Eylath U. Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J (Clin Res Ed) 1983; 286:1089.</a></li><li><a class="nounderline abstract_t">Supervía Caparrós A, Salgado García E, Calpe Perarnau X, et al. Immediate and 30 days mortality in digoxin poisoning cases attended in the Hospital Emergency Services of Catalonia, Spain. Emergencias 2019; 31:39.</a></li><li><a class="nounderline abstract_t">Ujhelyi MR, Green PJ, Cummings DM, et al. Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin fab antibodies. Ther Drug Monit 1992; 14:147.</a></li><li><a class="nounderline abstract_t">Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf 2004; 27:1115.</a></li><li><a class="nounderline abstract_t">Dasgupta A. Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol 2002; 118:132.</a></li><li><a class="nounderline abstract_t">Li-Saw-Hee FL, Lip GY. Digoxin revisited. QJM 1998; 91:259.</a></li><li><a class="nounderline abstract_t">Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992; 69:108G.</a></li><li><a class="nounderline abstract_t">Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81:1744.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.</a></li><li><a class="nounderline abstract_t">Brubacher JR, Ravikumar PR, Bania T, et al. Treatment of toad venom poisoning with digoxin-specific Fab fragments. Chest 1996; 110:1282.</a></li><li><a class="nounderline abstract_t">Cheung K, Urech R, Taylor L, et al. Plant cardiac glycosides and digoxin Fab antibody. J Paediatr Child Health 1991; 27:312.</a></li><li><a class="nounderline abstract_t">Smith TW, Haber E, Yeatman L, Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294:797.</a></li><li><a class="nounderline abstract_t">Woolf AD, Wenger T, Smith TW, Lovejoy FH Jr. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med 1992; 326:1739.</a></li><li><a class="nounderline abstract_t">de Silva HA, Fonseka MM, Pathmeswaran A, et al. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet 2003; 361:1935.</a></li><li><a class="nounderline abstract_t">Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 2008; 371:579.</a></li><li><a class="nounderline abstract_t">Henderson RP, Solomon CP. Use of cholestyramine in the treatment of digoxin intoxication. Arch Intern Med 1988; 148:745.</a></li><li><a class="nounderline abstract_t">Rawashdeh NM, al-Hadidi HF, Irshaid YM, Battah AK. Gastrointestinal dialysis of digoxin using cholestyramine. Pharmacol Toxicol 1993; 72:245.</a></li><li><a class="nounderline abstract_t">Manini AF, Nelson LS, Hoffman RS. Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. Am J Cardiovasc Drugs 2011; 11:173.</a></li><li><a class="nounderline abstract_t">Bower, JO, Mengle, HA. The additive effect of calcium and digitalis: a warning, with a report of two deaths. JAMA 1936; 106:1511.</a></li><li><a class="nounderline abstract_t">SHRAGER MW. Digitalis intoxication; a review and report of forty cases, with emphasis on etiology. AMA Arch Intern Med 1957; 100:881.</a></li><li><a class="nounderline abstract_t">Kne T, Brokaw M, Wax P. Fatality from calcium chloride in a chronic digoxin toxic patient. J Toxicol Clin Toxicol 1997; 5:505.</a></li><li><a class="nounderline abstract_t">Gold, H, Edwards, DJ. The effects of aubain on the heart in the presence of hypercalcemia. Am Heart J 1927; 3:45.</a></li><li><a class="nounderline abstract_t">Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J 1970; 79:499.</a></li><li><a class="nounderline abstract_t">Hack JB, Woody JH, Lewis DE, et al. The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a porcine model. J Toxicol Clin Toxicol 2004; 42:337.</a></li><li><a class="nounderline abstract_t">Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med 1996; 28:440.</a></li><li><a class="nounderline abstract_t">Van Deusen SK, Birkhahn RH, Gaeta TJ. Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity. J Toxicol Clin Toxicol 2003; 41:373.</a></li><li><a class="nounderline abstract_t">Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med 2011; 40:41.</a></li><li><a class="nounderline abstract_t">Renard C, Grene-Lerouge N, Beau N, et al. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol 1997; 44:135.</a></li><li><a class="nounderline abstract_t">Ujhelyi MR, Robert S, Cummings DM, et al. Disposition of digoxin immune Fab in patients with kidney failure. Clin Pharmacol Ther 1993; 54:388.</a></li><li><a class="nounderline abstract_t">Ujhelyi MR, Robert S, Cummings DM, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med 1993; 119:273.</a></li><li><a class="nounderline abstract_t">Warren SE, Fanestil DD. Digoxin overdose. Limitations of hemoperfusion-hemodialysis treatment. JAMA 1979; 242:2100.</a></li><li><a class="nounderline abstract_t">Slattery JT, Koup JR. Haemoperfusion in the management of digoxin toxicity: is it warranted? Clin Pharmacokinet 1979; 4:395.</a></li><li><a class="nounderline abstract_t">Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila) 2016; 54:103.</a></li><li><a class="nounderline abstract_t">Santos-Araújo C, Campos M, Gavina C, et al. Combined use of plasmapheresis and antidigoxin antibodies in a patient with severe digoxin intoxication and acute renal failure. Nephrol Dial Transplant 2007; 22:257.</a></li><li><a class="nounderline abstract_t">Rabetoy GM, Price CA, Findlay JW, Sailstad JM. Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis. Am J Nephrol 1990; 10:518.</a></li><li><a class="nounderline abstract_t">Gittelman MA, Stephan M, Perry H. Acute pediatric digoxin ingestion. Pediatr Emerg Care 1999; 15:359.</a></li><li><a class="nounderline abstract_t">Thacker D, Sharma J. Digoxin toxicity. Clin Pediatr (Phila) 2007; 46:276.</a></li></ol></div><div id="topicVersionRevision">Topic 319 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12007081" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Digoxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077654" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Digoxin Use and Associated Adverse Events Among Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10340832" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30529380" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3277052" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Digitalis. Mechanisms of action and clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752808" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Digoxin reduces cardiac sympathetic activity in severe congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752808" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Digoxin reduces cardiac sympathetic activity in severe congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757504" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207409" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Electrocardiographic manifestations: digitalis toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3904388" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10069797" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Digitalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1626491" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346128" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and treatment of digoxin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411543" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621387" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : P-glycoprotein-mediated intestinal and biliary digoxin transport in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14705869" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical relevance of P-glycoprotein in drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231118" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9262530" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The serum digoxin concentration: ten questions to ask.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945415" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fatal non-occlusive mesenteric infarction following digoxin intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3529634" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Digitalis toxicity--turning over a new leaf?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4715199" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768435" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10677410" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1997019" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recognition and management of digitalis intoxication: implications for emergency medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2999197" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : New advances in the assessment and treatment of digitalis toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6404339" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30656872" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immediate and 30 days mortality in digoxin poisoning cases attended in the Hospital Emergency Services of Catalonia, Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1585401" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin fab antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15554746" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fab antibody fragments: some applications in clinical toxicology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12109847" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9666948" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Digoxin revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1626485" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recognition and management of digitalis toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188752" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915235" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of toad venom poisoning with digoxin-specific Fab fragments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1931226" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Plant cardiac glycosides and digoxin Fab antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/943040" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1594015" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The use of digoxin-specific Fab fragments for severe digitalis intoxication in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12801736" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280328" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341874" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Use of cholestyramine in the treatment of digoxin intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372041" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Gastrointestinal dialysis of digoxin using cholestyramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21619380" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The additive effect of calcium and digitalis: a warning, with a report of two deaths</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13478196" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Digitalis intoxication; a review and report of forty cases, with emphasis on etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fatality from calcium chloride in a chronic digoxin toxic patient</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effects of aubain on the heart in the presence of hypercalcemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5418023" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Assessment of the synergistic relationship between serum calcium and digitalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461240" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a porcine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8839532" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hyperkalemia and digoxin toxicity in a patient with kidney failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12870880" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201134" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effects of intravenous calcium in patients with digoxin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9278197" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222481" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Disposition of digoxin immune Fab in patients with kidney failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8328735" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/490791" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Digoxin overdose. Limitations of hemoperfusion-hemodialysis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/509853" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Haemoperfusion in the management of digoxin toxicity: is it warranted?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26795743" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16963474" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Combined use of plasmapheresis and antidigoxin antibodies in a patient with severe digoxin intoxication and acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2075910" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10532672" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Acute pediatric digoxin ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17416888" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Digoxin toxicity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
